Amin Saba, Aung Myat, Gandhi Fenil R, Pena Escobar Julio A, Gulraiz Azouba, Malik Bilal Haider
Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2020 Sep 4;12(9):e10248. doi: 10.7759/cureus.10248.
Myasthenia gravis (MG) is a rare autoimmune neuromuscular junction disorder, and thyroid disorder is a disorder involving the thyroid receptor, of which Graves' disease (GD) is the most common autoimmune thyroid disorder, in which antibodies develop against thyroid receptors. Both may have similar clinical features. In myasthenia gravis, autoimmune antibodies develop against postsynaptic neuromuscular junction disrupting the neuromuscular transmission, resulting in fluctuating muscle weakness and fatigue. It is a disease of young women and older men. The two pathologies may coexist in a patient or can precede one another. Graves' disease (GD) among thyroid diseases is most often associated with MG. Similarities in clinical features lead to difficulty in distinguishing MG and GD. Despite the standard treatment of myasthenia gravis, including steroids, acetylcholinesterases, rituximab, immunosuppressants, and thymectomy, there is still an increased number of relapses and myasthenia crisis. Eculizumab and plasmapheresis are the two new treatment options for MG, with supporting evidence of marked improvement in recent studies. Myasthenia gravis and Graves' disease have a see-saw relationship. Treating one pathology may worsen the other, so physicians should always consider MG as a differential in patients of hyperthyroidism presenting with new symptoms of fatigue or respiratory failure or neuromuscular weakness. In this comprehensive review article, we tried to establish an association between myasthenia gravis and Graves' disease (GD) by exploring currently available literature from PubMed. However, more studies need to be done to establish an association between pathologies.
重症肌无力(MG)是一种罕见的自身免疫性神经肌肉接头疾病,而甲状腺疾病是一种涉及甲状腺受体的疾病,其中格雷夫斯病(GD)是最常见的自身免疫性甲状腺疾病,患者体内会产生针对甲状腺受体的抗体。两者可能具有相似的临床特征。在重症肌无力中,自身免疫抗体针对突触后神经肌肉接头产生,破坏神经肌肉传递,导致肌肉无力和疲劳症状波动。这是一种好发于年轻女性和老年男性的疾病。这两种病症可能在同一患者中共存,也可能先后出现。甲状腺疾病中的格雷夫斯病(GD)最常与重症肌无力相关。临床特征的相似性导致区分重症肌无力和GD存在困难。尽管对重症肌无力有标准治疗方法,包括使用类固醇、乙酰胆碱酯酶、利妥昔单抗、免疫抑制剂以及胸腺切除术,但复发和重症肌无力危象的数量仍在增加。依库珠单抗和血浆置换是治疗重症肌无力的两种新选择,近期研究有证据支持其能显著改善病情。重症肌无力和格雷夫斯病存在一种跷跷板关系。治疗一种病症可能会使另一种病症恶化,因此医生在面对出现疲劳、呼吸衰竭或神经肌肉无力等新症状的甲状腺功能亢进患者时,应始终将重症肌无力列为鉴别诊断之一。在这篇综合性综述文章中,我们试图通过查阅来自PubMed的现有文献,来建立重症肌无力与格雷夫斯病(GD)之间的关联。然而,还需要更多研究来确定这两种病症之间的关联。